But on a more sober tone. What about this burp?
DNDN did something about like that and had a bad kick in the side of the head. They turned it around and rock'n today. The entire Sector is rocking. DNDN leads that arena.


The investigation stems from allegations that BioSante issued materially false and misleading statements designed to artificially inflate the Company's stock price. In particular, the investigation concerns allegations that senior officials at BioSante misled investors about the commercial viability and effectiveness of LibiGel, an experimental compound intended to boost women's libido. On December 14, 2011, the Company disclosed that its product LibiGel failed to yield positive results in efficacy tests. Upon this news, shares of BioSante stock plummeted from a trading high of $2.65 on December 14, 2011 to a close of $0.48 on December 15, 2011.